Global survey of national tuberculosis drug policies

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 5, 2011, Pages 613-619

  Paydar, A ^a   Mak, A ^a   Al Jahdali, H ^b   Del Granado, M ^c   Zaleskis, R ^d   Mouzafarova, N ^e   Walters, L ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c PAN AMERICAN HEALTH ORGANIZATION   (United States)

^d WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^e WHO   (India)

Author keywords

Drug policy; Drug resistance; MDR TB; Treatment; Tuberculosis

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG MARKETING; HEALTH CARE AVAILABILITY; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; LOWEST INCOME GROUP; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; PHARMACY; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SHORT COURSE THERAPY;

ANTITUBERCULAR AGENTS; COMMERCE; HEALTH POLICY; HUMANS; NATIONAL HEALTH PROGRAMS; PREVALENCE; QUESTIONNAIRES; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79954529913     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0199     Document Type: Article

References (21)

1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
2. Abigail W, Zignol M, Van Deun A, et al. Epidemiology of anti-tuberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-tuberculosis Drug Resistance Surveillance. Lancet 2009; 373: 1861-1873.
3. Donald P R, Van Helden P D. The global burden of tuberculosis - combating drug resistance in difficult times. New Engl J Med 2009; 360: 2393-2395.
4. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance, 2002-2007. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008. http://www.who.int/tb/publications/2008/drs-report4-26feb08.pdf Accessed February 2011.
5. Rieder H L. Interventions for tuberculosis control and elimination. Paris, France: International Union Against Tuberculosis and Lung Disease, 2002.
6. Caminero J A. Treatment of multidrug resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837. (Pubitemid 44197841)
7. Uplekar M, Juvekar S, Morankar S, Rangan S, Nunn P. Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis 1998; 2: 324-329. (Pubitemid 28168310)
8. Lönnroth K, Thuong L M, Lambregts K, Quy H T, Diwan V K. Private tuberculosis care provision associated with poor treatment outcome: comparative study of a semi-private lung clinic and the NTP in two urban districts in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2003; 7: 165-171. (Pubitemid 36172678)
9. Laserson K F, Kenyon A S, Kenyon T A, Layloff T, Binkin N J. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 2001; 5: 448-454. (Pubitemid 32397569)
10. Hurtig A K, Pande S B, Baral S C, Porter J D H, Bam D S. Anti-tuberculosis treatment in private pharmacies, Kathmandu Valley, Nepal. Int J Tuberc Lung Dis 2000; 4: 730-736. (Pubitemid 30650031)
11. World Health Organization. Global tuberculosis control: surveillance, planning, financing: 2008. WHO/HTM/TB/2006.362. Geneva, Switzerland: WHO, 2008.
12. United Nations Programme on HIV-AIDS. 2006 report on the global AIDS epidemic. UNAIDS/06.20E. Geneva, Switzerland: UNAIDS.
13. World Bank. Gross national income - per capita. Washington DC, USA: World Bank, 2007. http://www.worldbank.org/data/countrydata/countrydata.html Accessed June 2007.
14. Dawson-Saunders B, Trapp R G. Basic and clinical biostatistics. Norwalk, CT, USA: Appleton & Lange, 1990.
15. Raviglione M C, Rieder H L, Styblo K, Khomenko A G, Esteves K, Kochi A. Tuberculosis trends in eastern Europe and the former USSR. Tubercle Lung Dis 1994; 75: 400-416.
16. Toungoussova O S, Bjune G, Caugant D A. Epidemic of tuberculosis in the former Soviet Union: social and biological reasons. Tuberculosis (Edinb) 2006; 86: 1-10.
17. Zalesky R, Abdullajev F, Khechinashvili G, Safarian M, et al. Tuberculosis control in the Caucasus: successes and constraints in DOTS implementation. Int J Tuberc Lung Dis 1999; 3: 394-401. (Pubitemid 29294689)
18. Lambert M-L, Delgado R, Michaux G, Volz A, Van der Stuyft P. Tuberculosis control and the private health sector in Bolivia: a survey of pharmacies. Int J Tuberc Lung Dis 2004; 8: 1325-1329. (Pubitemid 39611577)
19. Uchiyama Y, Mao T E, Okada K, Chay S, Kou Soum M, Leng C. An assessment survey of anti-tuberculosis drug management in Cambodia. Int J Tuberc Lung Dis 2006; 10: 153-159. (Pubitemid 43275538)
20. Schwalbe N R, Wells W A, Geaneotes A P, et al. Estimating the market for tuberculosis drugs in industrialized and developing nations. Int J Tuberc Lung Dis 2008; 12: 1173-1181.
21. van den Boogaard J, Semvua H H, Boeree M J, Aarnoutse R E, Kibiki G S. Sale of fluoroquinolones in northern Tanzania: a potential threat for fluoroquinolone use in tuberculosis treatment. J Antimicrob Chemother 2010; 65: 145-147.